Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Michael A NauckJohn B BuseJohannes F E MannStuart PocockHeidrun Bosch-TrabergHelle Frimer-LarsenQing YeAlastair Graynull null

Published in: Diabetes, obesity & metabolism (2018)

Liraglutide demonstrated a modest but significant benefit in patient-reported health status using the EQ-5D, compared with placebo. This benefit may be of clinical relevance and requires further study.

Keyphrases

patient reported
phase iii
clinical trial
study protocol
phase ii
double blind